Close
Solutions
Online Inquiry

CONTACT US

USA:
Europe: UK - Germany
Call us at:
USA:
Europe:
Fax:
Email:

One-Stop CAR-B Therapy Development

Over the past decade, great progress has been made in the field of immunotherapy, especially in the field of T cell therapy. Chimeric antigen receptor (CAR)-engineered T cell therapy is the most promising approach, which has shown remarkable ability in the elimination of a variety of tumors. While, as more studies focused on B cells, researchers have found that the engineered B cells also have great therapeutic potential in various diseases.

Based on advanced technology and years of research, Creative Biolabs has developed high-quality custom services covering the entire CAR-B therapy development process to best suit customer's technical, program, and budget requirements which can greatly assist customer's research, preclinical investigation, and clinical stage development.

Our CAR-B therapy development services harness the power of two main advantages:

Gene delivery:

As the best pseudotype candidate, using the LVs pseudotyped with the BaEV envelope to achieve efficient B-cell gene transfer, which can facilitate efficient transduction of resting and stimulated human B cells. This system will be useful in B cell lines, and the range of alternative glycoproteins can be screened for optimal infectivity.

Fig 1. Pseudotyping of lentiviral vectors.

Pseudotyping of lentiviral vectors.

CRISPR-Cas9-mediated replacement of endogenous antibodies with engineered emAbs targeting RSV, HIV-1, influenza, or EBV in primary human B cells.

B cell genome engineering:

CRISPR/Cas9 system has been widely used in recent years due to its advantages of high specificity, high activity, and simple design. The CRISPR design algorithms will be used to develop effective knock-out strategies to remove endogenous BCR (B cell receptor) expression from a B cell line.

Fig.2 CRISPR-Cas9-mediated replacement of endogenous antibodies with engineered emAbs targeting RSV, HIV-1, influenza, or EBV in primary human B cells.

Our one-stop CAR-B therapy development services include but not limited to:

One-Stop CAR-B Therapy Development

Biomarker Identification & Selection

  • De novo discovery of potential cancer biomarkers by multiple gene and protein analysis technologies
  • Selection of the most suitable CAR-B therapy targets with greater potency and lower toxicity

One-Stop CAR-B Therapy Development

CAR Design & Construction

  • Design and construction of CARs
  • SmartTM CAR platform for the next generation CAR discovery
  • Customized lentiviral or retroviral CAR construction

One-Stop CAR-B Therapy Development

CAR-B In Vitro Assay

  • CAR expression validation
  • CAR-B cell proliferation
  • Multiplex cytokine screening
  • Cytotoxicity test against target cells

One-Stop CAR-B Therapy Development

Hybridoma-Immunogenomic engineering Platform

A platform for the immunogenomic reprogramming of hybridoma cells, leading to the rapid generation of cell lines that both surface express and secrete full-length antibodies.

Creative Biolabs' scientists are dedicated to bringing together years of valuable experience to help our clients shorten the clinical study journey. We are committed to providing CAR-B development services to reduce the overall project development timeline for our clients. For further details, please don't hesitate to contact us and see how we can help you reach your clinical vision.

References

  1. Di Roberto, et al. A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation. Molecular Therapy. 2020, 28,12.
  2. Hung K L, et al. Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells. Molecular Therapy. 2018.
  3. Guerrero A G, et al. Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy. Viruses. 2020,12,1016.
  4. Moffett H F, et al. B cells engineered to express pathogen-specific antibodies protect against infection. Sci. Immunol. 2019.
  5. Pogson M, et al. Immunogenomic engineering of a plug-and-(dis) play hybridoma platform. Nature communications, 2016.

All services and products are only for lab research use, not for any clinical diagnosis or treatment.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.